Low PSA production in patients with high-grade prostate cancer is linked to suppressed AR signaling, with TP53 and RB1 mutations promoting neuroendocrine features [15] and PTEN loss activating the PI3K/AKT pathway [16]. This evidence concerns the gene AR and prostate cancer.